Penile Carcinoma — Management & Follow-Up Algorithm
Primary tumour treatment, regional lymph node management, multimodal chemo/radiotherapy and risk-adapted surveillance — aligned with the EAU–ASCO 2026 Penile Cancer Guidelines and Campbell-Walsh-Wein Urology.
1. Primary tumour treatment ▶
PeIN / Ta (non-invasive): circumcision (first-line) → topical 5-FU or imiquimod, or laser ablation (CO₂ / Nd:YAG) for biopsy-confirmed PeIN/Ta/T1. Re-biopsy if doubt; do not repeat a failed topical course.
↓
T1–T2 confined to glans/prepuce: organ-sparing surgery preferred — wide local excision, glansectomy ± glans resurfacing (graft reconstruction), or radiotherapy (EBRT ≥60Gy EQD2 + brachytherapy boost, or brachytherapy alone for lesions <4cm). Margin 5–10mm; frozen section only if margin status uncertain.
↓
T2 with possible corporal invasion: distal corporectomy with glansectomy (dissection deep to Buck's fascia); intraoperative frozen section of corporeal tips/urethra if margin uncertain.
↓
T3 (corpora cavernosa invaded): partial penectomy ± reconstruction (urethral centralisation / neoglans). Offer wider resection when local recurrence risk is high (bulky, high-grade); discuss functional trade-off with patient.
↓
T4 / large tumour not amenable to partial amputation: total penectomy + perineal urethrostomy, ± myocutaneous flap for large defects; consider total phallic reconstruction later.
↓
Non-resectable disease: induction (neoadjuvant) chemotherapy → surgery in responders, OR definitive chemoradiotherapy (RT with mitomycin-C/capecitabine or cisplatin sensitisation) if surgery refused/not feasible.
Local recurrence after organ-sparing surgery: repeat organ-sparing resection if no corporal invasion; otherwise partial/total amputation. Width of macroscopic margin can be minimal (>1mm) in low-risk tumours without survival penalty.
2. Regional lymph node management ▶
A. Clinically node-negative groin (cN0) — risk-stratified staging
| Risk group | Criteria | Management |
|---|---|---|
| Low risk | pTa / pTis / pT1a G1 (no LVI/PNI) | Surveillance only — risk of occult metastasis too low to justify invasive staging |
| Intermediate risk | pT1a G2 (no LVI/PNI) | Surgical staging (DSNB or ILND) or surveillance in frail/motivated patients able to comply with strict follow-up — case-by-case, shared decision |
| High risk | pT1b or higher (any grade); or T1 with LVI/PNI/poorly differentiated | Surgical LN staging recommended: Dynamic Sentinel Node Biopsy (DSNB) preferred where available (sensitivity 92–96%, complication rate 6–14%). If DSNB unavailable/declined → inguinal lymph node dissection (ILND — open or videoendoscopic) |
Perform inguinal ultrasound ± FNAC before DSNB in all cN0 patients undergoing surgical staging. If SN is positive on histology → proceed to ipsilateral completion ILND.
B. Clinically node-positive groin (cN1–cN2)
cN1 (single mobile inguinal node): fascial-sparing ILND or open radical ILND (rILND), sparing the saphenous vein if possible.
cN2 (multiple/bilateral mobile nodes): ipsilateral open rILND (saphenous-sparing). Consider neoadjuvant chemotherapy (cisplatin + taxane) first if bulky/bilateral, in preference to upfront surgery in chemo-fit patients.
Do NOT use videoendoscopic ILND outside a clinical trial for cN1–2 disease.
Complete inguinal (and pelvic, if indicated) nodal surgery within 3 months of diagnosis, unless neoadjuvant chemotherapy has been given.
C. Prophylactic pelvic lymph node dissection (PLND)
Offer pelvic LND (open or minimally invasive) if, on pathology of the inguinal specimen:
• ≥3 ipsilateral positive inguinal nodes, or
• Extranodal extension (ENE) present on any node.
• ≥3 ipsilateral positive inguinal nodes, or
• Extranodal extension (ENE) present on any node.
D. Clinical N3 disease (fixed/matted inguinal mass or clinical pelvic nodes)
Do not proceed straight to surgery (upfront debulking gives poor CSS/DFS ~3–6 months and high complication rates). Confirm diagnosis (biopsy if not already known) → stage with CT/PET-CT chest-abdomen-pelvis.
↓
Neoadjuvant chemotherapy (cisplatin + taxane-based; TIP or TPF, 4 cycles) in chemo-fit patients →
↓
Responders / no progression: consolidative surgery (rILND + ipsilateral simultaneous PLND, preferably in the same anaesthetic episode) 5–8 weeks after last chemo cycle.
Non-responders / unfit for chemo: re-evaluate — consider chemoradiotherapy or radiotherapy alone (45–50Gy) if unfit; palliative approach if truly unresectable.
Non-responders / unfit for chemo: re-evaluate — consider chemoradiotherapy or radiotherapy alone (45–50Gy) if unfit; palliative approach if truly unresectable.
3. Chemotherapy — when and what ▶
| Setting | Indication | Regimen | Notes |
|---|---|---|---|
| Neoadjuvant | cN3 (fixed inguinal mass or clinical pelvic nodes); bulky/bilateral cN2 in chemo-fit patients — preferred over upfront surgery | TIP (paclitaxel + ifosfamide + cisplatin) × 4 cycles — best evidence (ORR ~50%, pCR ~10%); TPF (docetaxel/cisplatin/5-FU) alternative | Surgery 5–8 weeks after last cycle in responders/non-progressors |
| Adjuvant | pN3 disease (ENE or pelvic node +ve) post-LND, especially if NAC not already given | Cisplatin/taxane-based, individualised | Evidence weak/level 4 — offer only after balanced risk–benefit discussion; not proven to improve OS in meta-analyses |
| Palliative / metastatic (1st line) | Distant metastatic disease, or unresectable/non-responding disease | Platinum-based: triplets TPF or TIP, or doublets PF (cisplatin+5-FU) or paclitaxel/carboplatin | Doublets generally better tolerated; avoid taxane-triplets in neuropathy/poor renal function |
| Palliative (2nd line) | Progression after 1st-line platinum | Single-agent vinflunine or taxane; consider clinical trial/basket immunotherapy trial (pembrolizumab, cabozantinib combinations) | Response rates low, median OS ~5–6 months; enrol in trials where possible |
Never use bleomycin (pulmonary toxicity risk — strong recommendation against). Immune checkpoint inhibitors (pembrolizumab, retifanlimab, atezolizumab) show modest single-agent activity (ORR ~17–39%) — best offered within clinical trials.
4. Radiotherapy — when and what dose ▶
| Setting | Indication | Typical dose |
|---|---|---|
| Primary tumour (organ-sparing) | Selected T1–T2 lesions (patient choice / not fit for surgery) | EBRT ≥60Gy EQD2 + brachy boost, or brachytherapy alone (lesions <4cm) |
| Preoperative (unfit for chemo, awaiting surgery) | Bulky nodes, chemo-ineligible | 45–50Gy conventional fractionation |
| Definitive chemoradiotherapy | Non-resectable primary or nodal disease; patient declines surgery | ~59.5Gy with concurrent mitomycin-C/capecitabine or cisplatin sensitisation |
| Adjuvant (postoperative) | pN2/pN3 disease (incl. after NAC); >2 positive inguinal nodes with negative PLND; extranodal extension | ≥54Gy for ENE; 57–60Gy for positive margins/gross residual disease (older, lower doses e.g. 50Gy showed high in-field failure) |
| Palliative | Symptom control — ulcerating groin disease, bone pain, dermal lymphatic spread | Standard palliative fractionation; retreatment may be needed |
Chemosensitisation is recommended alongside adjuvant/definitive RT wherever the patient can tolerate it. HPV-positive tumours may show better response to chemoradiotherapy.
5. Follow-up schedule ▶
| Follow-up group | Years 1–2 | Years 3–5 | Examinations | Minimum duration |
|---|---|---|---|---|
| Primary tumour — penile-preserving Rx | 3-monthly | 6-monthly | Physician/self-exam; repeat biopsy after topical/laser Rx for PeIN if in doubt | 5 years |
| Primary tumour — amputation (partial/total) | 3-monthly | Annually | Physician/self-exam | 5 years |
| Inguinal nodes — surveillance (low-risk, no surgical staging) | 3-monthly (yr1), 6-monthly (yr2) | 6-monthly | Physical/self-exam ± 3-monthly groin US/FNAC in yr 1 | 5 years |
| Inguinal nodes — pN0 (after DSNB/ILND, negative) | 3-monthly (yr1), 6-monthly (yr2) | No further LN follow-up required | Physical/self-exam ± groin US/FNAC yr1–2; may stop LN follow-up thereafter if capable of self-exam | 5 years |
| Inguinal/pelvic nodes — pN+ (positive) | 3-monthly | 6-monthly | Physical/self-exam + CT chest/abdomen/pelvis (or ¹⁸FDG-PET/CT) each visit | 5 years (longer/lifelong self-exam if sarcomatoid or high-risk histology) |
~80% of local recurrences occur within 2 years and >95% of regional/distant recurrences within 2 years — justifying intensive early surveillance tapering after year 2. After 5 years, follow-up may be safely stopped in patients reliably performing self-examination, with easy re-access to clinic. Assess for lymphoedema and psychosexual/QoL concerns at every visit; refer early to lymphoedema therapy and psychology/counselling services. Manage all patients within a specialist multidisciplinary penile cancer centre.
Produced by Dr. Mohit Sharma, UROWALA
Based on the EAU–ASCO 2026 Collaborative Guidelines on Penile Cancer (uroweb.org/guidelines/penile-cancer) and Campbell-Walsh-Wein Urology, cross-checked against ASCO/EAU 2023 update literature. This tool is an educational summary for clinicians and does not replace the full guideline text, multidisciplinary tumour-board discussion, or individualised clinical judgement. Always verify staging, chemo-fitness, and dosing against the current full-text guideline and institutional protocol before treatment decisions.